22 results about "Proteinuria" patented technology

The application provides use of zanamivir in preparation of a medicine for treating or preventing preeclampsia, and a corresponding medicine and treatment method; zanamivir can effectively improve high blood pressure, proteinuria, creatinine, neuraminidase and sialic acid elevation symptoms of preeclampsia, increase NO level, and improve pregnancy outcome. Zanamivir and hydroxyprogesterone caproate in combination show better effects.

The embodiment of the present specification provides an antibody or antigen binding fragment binding to Helicobacter pylori antigen protein urease, the antibody or antigen binding fragment comprising a heavy chain variable region and a light chain variable region. Wherein, the heavy chain variable region comprises CDRH1 of an amino acid sequence as shown in SEQ ID NO: 2, CDRH2 of an amino acid sequence as shown in SEQ ID NO: 3 and CDRH of an amino acid sequence as shown in SEQ ID NO: 4. The light chain variable region comprises CDRL1 of an amino acid sequence as shown in SEQ ID NO: 6, CDRL2 of an amino acid sequence of DTS and CDRL3 of an amino acid sequence as shown in SEQ ID NO: 7. The antibody or antigen binding fragment has the characteristics of high purity, high specificity and sensitivity. The embodiment of the present specification also provides related application of the antibody or antigen binding fragment binding to Helicobacter pylori antigen protein urease.

The invention discloses a construction method of a spontaneous lupus adipositis animal model, which comprises the following steps: constructing keratinocytes with genotypes of PPAR [gamma] flox / flox- / -Krt5-CreERT < 2 + > / -Adipoq-Cre < + > / -and PPAR [gamma] flox / flox- / -Krt5-CreERT < 2 + > / -Adipoq-CreERT < 2 + > / -and fat cells into a conditional PPAR [gamma]-active receptor gamma gene knockout mouse, so as to construct the animal model with the spontaneous lupus adipositis animal model. Then knocking out PPAR gamma genes in keratinocytes and adipocytes by using a gene knockout activator, so that the mice spontaneously have the phenotypes of lupus septicaemia, including local skin unhairing, lipoatrophy, persistent skin lesion, proteinuria and serum autoantibodies; histological examination finds that lobular adipositis, glomerular volume increase, mesangial cell hyperplasia, inflammatory cell infiltration, glomerular IgG deposition and the like are mainly caused by dermal immune cell infiltration and subcutaneous fat layer lymphocyte infiltration, clinical symptoms of patients with lupus adipositis are simulated, and an important tool is provided for related research of lupus adipositis.

The present invention relates to novel polymorphic forms of Iptacopan hydrochloride and preparation thereof. The invention also relates to pharmaceutical composition comprising novel polymorphic forms of Iptacopan hydrochloride and their use in the treatment of paroxysmal nocturnal hemoglobinuria and proteinuria.

Methods for treating high proteinuria chronic kidney disease and / or at least one disease, disorder, or condition associated therewith in patients by the use of a fixed-dose combination of zibotentan and dapagliflozin are disclosed.

The utility model discloses a urine formation dynamic demonstration instrument capable of segmentally demonstrating, which comprises a nephrology main body structure model, a display board bracket, a solution collector, a circulating water pump, an appendage part and a liquid simulation part, the renal unit main body structure model comprises a glomerulus model, a renal capsule model, a renal tubule model, a filter screen, a globular arteriole model, a globular arteriole model, a renal vein model and a capillary model; the filter screen is embedded at the bottom of a sphere of the glomerular model; the glomerulus model, the kidney capsule model, the bulblet arteriole model and the capillary model penetrate through the display board bracket and extend to the corresponding solution collectors; wherein one end of one renal tubule model passes through the display board bracket and extends to the corresponding solution collector, and the other end extends to the corresponding solution collector on the front side of the display board bracket. According to the utility model, not only can the urine formation process be visually demonstrated, but also students can understand the occurrence mechanism of diseases such as proteinuria and hematuria caused by urinary organ abnormity.

The invention discloses a biomarker for detecting renal fibrosis, application and a system, and relates to the technical field of biological medicines. The invention relates to a biomarker for detecting renal fibrosis. The biomarker comprises urinary copper cyanin. Compared with the conventional diagnostic marker (such as eGFR, RBP, NAG and the like), the urocyanin has the following three advantages: 1, compared with the conventional diagnostic marker (such as eGFR, RBP, NAG and the like), the urocyanin is more sensitive to diagnosis of renal interstitial fibrosis and fibrosis severity; secondly, compared with traumatic renal tissue pathologic biopsy, urine is used as a diagnosis medium, so that true noninvasive effect can be realized, and no harm is caused to the body health of a patient; and thirdly, compared with detection means such as iconography, the method for detecting the urinary cupreocyanin marker is lower in cost, more flexible, high in timeliness and easier to popularize.

The traditional Chinese medicine composition disclosed by the invention adopts a method of warming yang and relieving exterior syndrome to achieve the effects of freeing lung and inducing diuresis, tonifying spleen and warming kidney, and strengthening defensive qi and diminishing swelling, and is prepared to be used for treating the immune-related glomerular diseases, especially membranous nephropathy and minimal lesion nephropathy. The traditional Chinese medicine composition is a pure traditional Chinese medicine preparation, clinical observation and in-vivo and in-vitro basic tests show that the prescription can remarkably improve edema, massive proteinuria, hypoproteinemia and the like, meanwhile, compared with the prior art, the traditional Chinese medicine composition has a better effect on symptoms such as stomachache and diarrhea, has an anti-inflammatory effect and does not have obvious side effects in clinical application. The traditional Chinese medicine composition has an excellent effect on patients suffering from membranous nephropathy and minimal lesion nephropathy caused by syndrome differentiation of spleen-kidney yang deficiency, internal rheumatism and water-fluid overflowing.

This invention discloses an engineered extracellular vesicle and its application in the preparation of products for treating autoimmune diseases. The engineered extracellular vesicle is either an IDO1-overexpressing engineered extracellular vesicle (MSC-IDO1-EVs) or a CSF1-overexpressing engineered extracellular vesicle (MSC-CSF1-EVs). The engineered extracellular vesicles provided by this invention exhibit significant immunosuppressive effects, reducing the secretion of inflammatory cytokines. In animal models, they effectively reduce proteinuria levels, significantly reduce blood dsDNA / ANA levels, effectively alleviate kidney damage caused by autoimmune diseases such as renal immune complex deposition, diffuse thickening of the glomerular basement membrane, and mesangial structural disorder, and reduce overall inflammation levels in mice. The therapeutic effect is significantly superior to that of unmodified MSC-EVs. The engineered extracellular vesicles provided by this invention significantly improve the therapeutic effect on autoimmune diseases.

The application discloses application of an E3 ubiquitin ligase SIAH2 inhibitor in preparation of a lupus nephritis kidney protection drug. Researches of the application show that the SIAH2-LATS2 axis participates in the pathogenic process of kidney fibrosis of lupus nephritis, and it is confirmed that LATS2 can be used as a target point for preventing fibrosis progression in lupus nephritis. It is shown that LATS2 is abnormally down-regulated in lupus nephritis, and the use of an E3 ubiquitin ligase SIAH2 inhibitor can restore the LATS2 level, reduce the production of a LATS2 downstream gene CTGF, reduce the occurrence of interstitial fibrosis, reduce the proteinuria effect of lupus nephritis, thereby protecting the kidney function and delaying the progression of lupus nephritis. The application uses the SIAH2 inhibitor vitamin K3, which can prevent the conversion of lupus nephritis to ESRD, and can be used as an effective drug for treating and preventing kidney fibrosis, and provides a new selection for lupus nephritis treatment drugs and fibrosis prevention and treatment drugs.

The invention discloses a method for constructing a spontaneous systemic lupus erythematosus animal model, which comprises the following steps: knocking out EP300 (E1A Binding Protein P300) in keratinocytes to enable a mouse to spontaneously have systemic lupus erythematosus phenotypes, including local skin unhairing, persistent skin lesion, persistent proteinuria and serum autoantibodies; the systemic lupus erythematosus sample changes such as dermal immune cell infiltration and glomerular IgG deposition exist in histological examination, clinical symptoms of systemic lupus erythematosus are simulated, and an important tool is provided for related research of systemic lupus erythematosus.

The present disclosure relates to methods related to the treatment of IgA nephropathy. More specifically, the present disclosure relates to methods for treating a patient having IgA nephropathy (IgAN), to methods for reducing the serum Gd-IgA1 level in a patient having IgA nephropathy (IgAN), to methods for reducing the proteinuria in a patient having IgA nephropathy, to methods for reducing the serum Gd-IgA1 level and the proteinuria in a patient having IgA nephropathy, and further related disclosure.

The present disclosure relates to methods related to the treatment of IgA nephropathy. More specifically, the present disclosure relates to methods for treating a patient having IgA nephropathy (IgAN), to methods for reducing the serum Gd-IgA1 level in a patient having IgA nephropathy (IgAN), to methods for reducing the proteinuria in a patient having IgA nephropathy, to methods for reducing the serum Gd-IgA1 level and the proteinuria in a patient having IgA nephropathy, and further related disclosure.

Disclosed in the present invention is the use of a water extract of Amomi fructus and / or a vanillic acid in the preparation of a drug for preventing and / or treating preeclampsia. Further disclosed in the present invention is the use of the water extract of Amomi fructus and / or the vanillic acid in the preparation of a drug for preventing and / or treating hypertension caused by preeclampsia, or a drug for preventing and / or treating proteinuria caused by preeclampsia, or a drug for reversing a reduction in placental weight caused by preeclampsia, or a drug for restoring fetal intrauterine growth restrictions caused by preeclampsia, or a drug for restoring pathological damage to placental tissue or placental dysfunction caused by preeclampsia, or a drug for reversing the reduction in placental efficiency caused by preeclampsia, or a drug for repairing colonic barrier damage or increased intestinal permeability caused by preeclampsia, or a drug for enriching the intestinal tract of a patient with preeclampsia with Bifidobacterium bifidum. The present invention overcomes the limitations of current drugs for treating preeclampsia which exhibit limited single therapeutic effects and gastrointestinal adverse reactions.

The application belongs to the field of biological medicine, and provides application of inosine in preparation of a drug for preventing and / or treating preeclampsia. The pathological state of preeclampsia is simulated by subcutaneous injection of a solution of nitroso-L-arginine methyl ester (125 mg / kg). From the 9th day of pregnancy, inosine is administered by gavage once a day (100 mg / kg), until the end of pregnancy. Compared with drugs such as labetalol, magnesium sulfate and other drugs with single treatment effect, the application proves that oral inosine can not only significantly improve hypertension and proteinuria caused by preeclampsia, repair placental function, promote intrauterine growth and development of the fetus, correct the imbalance of vascular and anti-angiogenic factors, but also reduce the damage to the kidneys and brain of pregnant women induced by preeclampsia, and exhibits a more comprehensive treatment effect, thereby providing a new therapeutic drug for preventing or treating preeclampsia.

This invention relates to a traditional Chinese medicine composition for delaying the progression of kidney deficiency and blood stasis syndrome in diabetic nephropathy, its application, and preparation method. The composition is made from Astragalus membranaceus, Salvia miltiorrhiza, Paeonia lactiflora, Anemarrhena asphodeloides, Phellodendron chinense, Cistanche deserticola, Scutellaria baicalensis, Euonymus alatus, Schisandra chinensis, raw oyster shell, Plantago asiatica, and Artemisia annua. It has the effects of nourishing the kidneys, clearing heat, eliminating toxins, and unblocking the meridians. This traditional Chinese medicine composition can effectively delay the decline in renal function in patients with massive proteinuria during the diabetic nephropathy stage, improve the clinical symptoms of patients with kidney deficiency and blood stasis syndrome, and improve their quality of life. Simultaneously, it has a low risk of hyperkalemia and gastrointestinal bleeding, and no significant damage to liver function has been observed, indicating high safety.

The present application belongs to the technical field of biological medicine, and particularly relates to the use of a secreted lactase-like protein (LCTL) as a diagnostic marker in the preparation of a chronic kidney disease diagnostic kit. The present application first discovers that LCTL exists in a secreted form, first detects the content of secreted LCTL in human serum by using an existing commercial ELISA kit, further research finds that the content of secreted LCTL in serum of patients with chronic kidney disease is significantly lower than that of normal people, and the content of LCTL in serum is significantly related to the degree of kidney function damage and the degree of proteinuria of patients, and therefore the use of secreted LCTL in the preparation of a biomarker for the diagnosis of chronic kidney disease is first proposed. The present application provides a new method for the diagnosis of chronic kidney disease, and has great clinical significance and commercial value.

The present application relates to the field of medicine, and more particularly to the use of aesculin or verbascoside in the preparation of a medicament for treating and / or preventing IgAN. The present inventors have found that aesculin and / or verbascoside can significantly improve proteinuria caused by IgAN and reduce inflammatory reactions, thereby playing a role in protecting kidney function, and do not have the serious shortcomings of clinically commonly used drugs, indicating that aesculin and / or verbascoside have a strong and low-toxicity effect in treating IgAN. In addition, aesculin and / or verbascoside are a natural compound, low toxicity and easy to be accepted by the human body.

To provide new agents capable of inhibiting the progression of chronic kidney disease.SOLUTION: A chronic kidney disease progression inhibitor is prepared that includes dantrolene or a pharmaceutically acceptable salt thereof, or a hydrate of them as an active ingredient. Preferably, the inhibitor is applied to chronic kidney disease involving proteinuria and / or glomerulosclerosis and is administered to a patient who has undergone kidney removal or a patient after renal infarction.SELECTED DRAWING: Figure 2

This application discloses Ropsacitinib, a selective tyrosine kinase 2 (TYK2) inhibitor for the treatment of systemic lupus erythematosus (SLE), and its application. In vitro experiments demonstrated that Ropsacitinib can selectively inhibit the production of key cytokines such as type I interferon (IFNα) and IL6 with nanomolar-level potency in a dose-dependent manner. In vivo experiments systematically evaluated the therapeutic effects and mechanism of action of Ropsacitinib on SLE. Results showed that Ropsacitinib significantly improved weight loss, proteinuria, and skin lesions in SLE model mice, alleviated pathological damage to the kidneys and spleen, and fundamentally restored the disordered immune cell balance. This application provides scientific evidence for Ropsacitinib as a safe and effective precision treatment for SLE.

Inventors have explored the relevance of alpelisib in MRL / MpJ-Faslpr / J mice (referred here as MRL-lpr). a mouse model of lupus nephritis. MRL-lpr mice treated with alpelisib demonstrated less proteinuria compared to vehicle. More stinkingly, comparison of albuminuria before and after treatment introduction showed opposite trajectories. Indeed. MRL-lpr mice treated with alpelisib demonstrated proteinuria improvement arguing for a reversibility of the disease. At sacrifice. MRL-lpr mice treated with alpelisib had a tendency to have a lower kidney to body weight ratio compared to vehicle treated animals. Kidney examination showed that alpelisib was associated with no glomerular lesions compared to vehicle treated mice and an improved kidney function. Inventors conclude that alpelisib and more generally PIK3CA inhibition represent promising drugs for patients with proliferative glomerulonephritis. The invention relates to a method for treating proliferative glomerulonephritis in a subject in need thereof comprising a step of administering the subject with a therapeutically effective amount of a PIK3CA inhibitor.

The application belongs to the technical field of proteinuria treatment drugs, and relates to application of a lipid gold nanoparticle complex in preparation of a proteinuria treatment drug. The lipid gold nanoparticle complex is composed of a cationic liposome, a gold nanoparticle complex and a targeting peptide. The cationic liposome coats the gold nanoparticle complex, and the targeting peptide is loaded on the surface of the cationic liposome after coating the gold nanoparticle complex. The gold nanoparticle complex is a complex of a gold nanoparticle and a VE-Cadherin overexpression plasmid. The sequence of the VE-Cadherin overexpression plasmid is shown as SEQ ID NO. 1, and the sequence of the targeting peptide is shown as SEQ ID NO. 2. The lipid gold nanoparticle complex provided by the application can repair the glomerular filtration barrier, thereby improving permeability, and further achieving treatment of proteinuria.